Guardant Health (GH) AI Stock Analysis

• Market Cap: $6.14B
• Dividend Yield: N/A
• Average Volume (3M): 2.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: 28.20%
• EPS Growth: 13.87%
• Country: US
• Employees: 1,999
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.77
• Shares Outstanding: 123,888,050
• 10 Day Avg. Volume: 1,756,344
• 30 Day Avg. Volume: 2,039,304
• PEG Ratio: -0.06
• Price to Book (P/B): 46.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.18
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 2.45
• Enterprise Value/Gross Profit: 14.68
• Enterprise Value/Ebitda: -4.10
• 1Y Price Target: $60.65
• Price Target Upside: 19.34% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 57 Neutral
• Price Target: $49.00 ▼(-3.58%Downside)

Guardant Health's overall stock score is primarily impacted by its financial performance challenges, including high leverage and cash flow issues, despite strong revenue growth. Positive technical indicators and a favorable earnings call provide some support, but valuation concerns remain due to ongoing losses.

Positive Factors

Guideline Inclusion

Shield has been included in NCCN colorectal screening guidelines, which is expected to help drive community adoption and commercial payor reimbursement.

Market Expansion

Flagship G360 assay shows no sign of slowing and has room to expand into underpenetrated areas.

Regulatory Approval

Shield MCED received a Breakthrough Device designation from the FDA, highlighting its potential impact in the diagnostics market.

Negative Factors

Assay Performance

The performance of the Shield MCD assay could degrade with a larger pivotal and registrational trial, as observed with other screening assays.

Competitive Pressure

Upcoming blood-based colorectal cancer screening data from a competitor may cause a near-term overhang for Guardant Health shares.

Sensitivity Concerns

Shield's AA sensitivity of 13% is lower than other recommended colorectal screening modalities.

Guardant Health Business Overview & Revenue Model

Company Description

Guardant Health, Inc. is a leading precision oncology company that specializes in blood tests, data analytics, and advanced technology to improve cancer detection, treatment, and monitoring. The company operates primarily in the biotechnology and healthcare sectors, offering innovative liquid biopsy tests that enable comprehensive genomic profiling of cancer through a simple blood draw. Guardant Health's core products include Guardant360, GuardantOMNI, and Guardant Reveal, which are used for cancer detection, therapy selection, and recurrence monitoring, respectively.

How the Company Makes Money

Guardant Health generates revenue primarily through the sale of its proprietary liquid biopsy tests to healthcare providers, pharmaceutical companies, and research institutions. The key revenue streams include diagnostic testing services, including Guardant360, GuardantOMNI, and Guardant Reveal, which are billed to insurance companies, healthcare providers, and directly to patients. Additionally, the company partners with biopharmaceutical companies to provide testing services for clinical trials, which offers another significant revenue source. These partnerships help in the development and commercialization of new cancer therapies and diagnostics. Guardant Health's revenue is further supported by its extensive database of genomic information, which it leverages to offer data analytics services and research collaborations.

Guardant Health Financial Statement Overview

Summary

Despite strong revenue growth, Guardant Health faces significant financial challenges with ongoing net losses, high leverage, negative equity, and cash flow issues. These factors weigh heavily on the financial stability and require strategic changes for improvement.

Income Statement

Guardant Health's revenue has seen consistent growth over the years, with a notable increase from $286.7 million in 2020 to $774 million in TTM 2025. However, the company continues to operate at a net loss, with negative EBIT and EBITDA margins, indicating ongoing profitability challenges. The gross profit margin is relatively stable, but the net profit margin remains negative, impacting the overall financial performance.

Balance Sheet

The balance sheet reveals a highly leveraged position with a significant negative stockholders' equity as of TTM 2025, indicating potential solvency issues. The debt-to-equity ratio is unfavorable due to the negative equity, and the equity ratio shows a lack of equity backing the total assets. This financial structure poses risks to the company's financial health and stability.

Cash Flow

Guardant Health has struggled with negative operating and free cash flows, although there is a slight improvement in free cash flow growth recently. The operating cash flow to net income ratio is negative, reflecting cash flow challenges relative to its net losses. The company needs to improve cash generation to support its operations sustainably.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	774.00M	739.02M	563.95M	449.54M	373.65M	286.73M
Gross Profit	474.77M	449.22M	336.90M	293.21M	250.74M	194.19M
EBITDA	-397.86M	-390.12M	-433.31M	-614.91M	-359.62M	-225.07M
Net Income	-416.55M	-436.37M	-479.45M	-654.59M	-384.77M	-246.28M
Balance Sheet
Total Assets	1.34B	1.49B	1.79B	1.61B	2.20B	2.27B
Cash, Cash Equivalents and Short-Term Investments	698.57M	839.98M	1.17B	1.01B	932.75M	1.79B
Total Debt	1.31B	1.34B	1.35B	1.37B	1.36B	847.86M
Total Liabilities	1.60B	1.63B	1.63B	1.55B	1.56B	916.19M
Stockholders Equity	-250.79M	-139.65M	158.68M	60.18M	645.00M	1.30B
Cash Flow
Free Cash Flow	-304.87M	-274.94M	-345.46M	-386.92M	-284.05M	-157.99M
Operating Cash Flow	-272.26M	-239.86M	-324.98M	-309.46M	-209.02M	-103.93M
Investing Cash Flow	13.49M	-261.31M	840.25M	149.82M	-63.16M	-617.09M
Financing Cash Flow	-66.77M	-996.00K	477.38M	-189.09M	-66.82M	1.41B

Guardant Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 50.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GH, the sentiment is Positive. The current price of 50.82 is above the 20-day moving average (MA) of 49.93, above the 50-day MA of 45.65, and above the 200-day MA of 38.11, indicating a bullish trend. The MACD of 1.50 indicates Positive momentum. The RSI at 60.30 is Neutral, neither overbought nor oversold. The STOCH value of 43.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GH.

Guardant Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTRA	73 Outperform	$21.67B	―	-18.66%	―	51.50%	53.23%
MEDP	72 Outperform	$9.17B	24.61	65.82%	―	9.87%	32.81%
SHC	61 Neutral	$3.24B	133.83	5.88%	―	2.78%	-54.72%
GH	57 Neutral	$6.14B	―	-4584.47%	―	28.20%	13.87%
EXAS	57 Neutral	$9.90B	―	-36.89%	―	11.57%	-315.25%
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
TEM	51 Neutral	$10.04B	―	-1252.79%	―	42.93%	-160.27%

Guardant Health Corporate Events

Guardant Health Elects Board and Approves Auditor

At the annual meeting of stockholders held on June 18, 2025, Guardant Health, Inc. elected all nominees for its board of directors, including Vijaya Gadde, Roberto Mignone, Myrtle Potter, and Musa Tariq. Additionally, the stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for 2025 and endorsed the compensation of the company’s named executive officers.

The most recent analyst rating on (GH) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Guardant Health stock, see the GH Stock Forecast page.